Valiant Laboratories Limited
Source: NSE · Updated 4 Nov, 06:28 pm IST
Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals and the filing PDF.
Quarter comparison
| Item | Q2 FY27 (Sep ’26) | Q1 FY27 (Jun ’26) | vs Q1 FY27 | Q2 FY26 (Sep ’25) | vs Q2 FY26 |
|---|---|---|---|---|---|
| Revenue from operations | 11,677.32 | — | — | 4,620.24 | ▲ 152.7% |
| Other income | 11.43 | 86.03 | ▼ 86.7% | 86.6 | ▼ 86.8% |
| Total expenses | 11,621.87 | 8,995.49 | ▲ 29.2% | 4,679.19 | ▲ 148.4% |
| Operating profit (EBITDA)* | 516.93 | — | — | 7.86 | ▲ 6476.7% |
| Profit before tax | 66.88 | 2,619.05 | ▼ 97.4% | 27.65 | ▲ 141.9% |
| Tax expense | 25.54 | 508.75 | ▼ 95.0% | 7.64 | ▲ 234.3% |
| Net profit | 41.34 | 2,110.3 | ▼ 98.0% | 20.01 | ▲ 106.6% |
| EPS (₹) | 0.08 | 3.89 | ▼ 97.9% | 0.04 | ▲ 100.0% |
| Operating margin | 4.4% | — | — | 0.2% | +420 bps |
| Net margin | 0.4% | — | — | 0.4% | +0 bps |
Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).
Figures in ₹ lakhs except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.
All Valiant Laboratories results, dividends & filings ›Other results filed 2 Nov
FAQ
When did Valiant Laboratories announce Q2 FY27 results?
Valiant Laboratories filed its results on NSE on 2 Nov, 06:59 pm IST.
What does QoQ and YoY mean?
QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.
Are these Valiant Laboratories figures official?
They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.
Explore
Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.
← VALIANTLAB overviewNothing matches.